FGF2 and B-cell chronic lymphocytic leukemia: The study provides the first evidence that +936 C>T VEGFA and c.233C>T bFGF polymorphisms may influence the risk of B-CLL, since the results show that both are closely related to protective phenotype, and increased overall and disease free survival prediction, which could be applied as novel biomarkers to identify individuals at high risk of the disease.